Ezetimibe Is an Inhibitor of Tumor Angiogenesis

Keith R. Solomon,*‡ Kristine Pelton,† Kelly Boucher,† Jinsoo Joo,† Christopher Tully,† David Zurakowski,† Carl P. Schaffner,§ Jayoung Kim,‡¶ and Michael R. Freeman‡¶

From the Departments of Orthopaedic Surgery,* Surgery,¶ and Biological Chemistry and Molecular Pharmacology,† Harvard Medical School, Boston, Massachusetts; the Departments of Orthopaedic Surgery,† and Urology,‡ Children's Hospital Boston, Boston, Massachusetts; and the Department of Microbiology and Biochemistry,§ Waksman Institute, Rutgers, the State University of New Jersey, New Brunswick, New Jersey

Epidemiological and preclinical observations have suggested a role for one or more products of the mevalonate/cholesterol biosynthesis pathway in the progression of prostate cancer. In this study, we used ezetimibe (Zetia), a specific, FDA-approved, cholesterol uptake-blocking drug, in combination with either a hyper- or hypocholesterolemic diet, to show that elevated circulating cholesterol levels promote, whereas a reduction in circulating cholesterol levels retard, the growth of human prostate cancer xenograft tumors in mice. Circulating cholesterol levels also modified tumor angiogenesis; higher cholesterol levels increased microvessel density and other indicators of vascularity. Consistent with these data, the reduction of cholesterol levels also increased the levels of the angiogenesis inhibitor thrombospondin-1 in the xenografts. Our results thus suggest that hypercholesterolemia directly accelerates the growth of prostate carcinomas, and that the pharmacological reduction of serum cholesterol levels may retard prostate cancer growth by inhibiting tumor angiogenesis. (Am J Pathol 2009, 174:1017–1026; DOI: 10.2353/ajpath.2009.080551)

Prostate cancer (PCa) and normal aging prostate tissue accumulate high levels of cholesterol.1–3 A role for high levels of serum cholesterol in PCa incidence and progression has been suggested through a number of epidemiological and preclinical studies.1,4–15 High fat/high cholesterol 'Western' diets have been linked to PCa incidence and progression in a number of reports, however a role for specific dietary components in disease progression is in dispute.16,17 Studies examining groups of nutritional components eaten together suggest that diets with a high content of processed and/or red meat may be associated with higher PCa incidence.18,19 In addition, some (but not all) studies of cholesterol-lowering drug use (ie, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, aka statins) and cancer incidence have shown a negative association between statin use and PCAs incidence and/or progression, including a significant reduction in risk of advanced disease with long-term statin use.4–7,10 Interestingly, meta-analyses of placebo-controlled studies have not supported a link between statins and PCa incidence.20–22 Although these studies have raised a number of concerns,23–25 they do illustrate that aspects of statin dose, duration, type, and mechanism of anti-cancer action likely need to be considered when determining whether statins affect PCa incidence or rates of progression.

Cholesterol is a neutral lipid that plays an important pathological role in cardiovascular disease. Statin drugs have been tested as potential chemotherapeutic agents in a number of experimental contexts, however few studies to date have been designed to assess the role specifically of cholesterol—in isolation from other factors—in cancer growth and progression. Statins interfere with the mevalonoid acid/cholesterol synthesis pathway at an early step, thereby blocking formation of isoprenoid intermediates necessary for lipidation of critical signaling proteins, such as the Ras family of guanosine triphosphatases. In cell culture and in animal studies, it is apparent that statins do affect isoprenylation because bypassing isoprenoid synthesis inhibition reverses statin-induced apoptosis.26 Effects on isoprenoid synthesis have been proposed as the underlying mechanism for the drugs' anti-tumor effects.27–35 However, this mechanism is contentious because statins, at standard doses, may not accumulate in peripheral tissues in a concentration sufficient to interfere with isoprenoid synthesis.36–38 Supported by NIH grants R01 CA101046 to K.R.S., R37 DK47556, R01 CA112303 to M.R.F., and US Army DoD grant PC050337 to M.R.F., and the Japan Foundation for Aging and Health.

Accepted for publication November 12, 2008.

Address reprint requests to Keith R. Solomon, Ph.D., Dept. of Orthopaedic Surgery, Children's Hospital Boston, Enders 1030, 300 Longwood Avenue, Boston, MA 02115. E-mail: keith.solomon@childrens.harvard.edu
In a previous study we demonstrated that the atherogenic Paigen diet, which causes hypercholesterolemia, stimulates growth of LNCaP human PCa xenografts. Tumors in the hypercholesterolemic environment accumulated cholesterol in lipid raft membranes, exhibited lower levels of apoptosis, and enhanced activation of Akt, a serine-threonine kinase linked to aggressive cancers. In explaining these results, we proposed that cholesterol may be directly contributing to tumor growth by altering signal transduction through effects on lipid rafts.

In the present study we isolated cholesterol from other potential factors, such as isoprenoids, using ezetimibe, a cholesterol-lowering drug that binds to and blocks NPC1L1, the gut transporter responsible for dietary and biliary cholesterol absorption. Our findings, using this drug in combination with other approaches, support a direct role for circulating cholesterol in the promotion of tumor growth and further suggest that an underlying mechanism of this effect occurs at the level of tumor angiogenesis.

**Materials and Methods**

**Antibodies**

The following antibodies were obtained from the sources indicated: anti-CD31 mAb (rat anti-mouse) and anti-caveolin pAb (BD Pharmingen, San Jose, CA); anti-thrombospondin-1 pAb, anti-caveolin-1 pAb, and anti-Ki-67 pAb (Abcam, Cambridge, MA); anti-β actin mAb and anti-smooth muscle actin mAb (Sigma, St Louis, MO); anti-phosphotyrosine mAb (Cell Signaling, Danvers, MA); anti-fibroblast mAb (Santa Cruz Biotechnology, Santa Cruz, CA); Alexa Fluor 488-conjugated goat anti-rat, Alexa Fluor 488-conjugated goat anti-mouse, Alexa Fluor 568-conjugated goat anti-rabbit, Alexa Fluor 568-conjugated goat anti-mouse (Invitrogen, Carlsbad, CA); and Cy3-conjugated AffiniPure goat anti-rabbit IgG, Fc fragment specific (Jackson ImmunoResearch, West Grove, PA).

**Mice and Tumor Xenografts**

Five-week-old SCID mice were obtained from the Massachusetts General Hospital and were fed a low fat/no cholesterol diet (LFNC) (Research Diets, New Brunswick, NJ diet # D12102) for 2 weeks, blood was drawn from the saphenous tail vein, and the serum cholesterol concentration was determined using the Infinity Cholesterol Liquid Stable Reagent (Thermo Electron Corp., Waltham, MA). The mice were then divided into high fat/high cholesterol diet (HFHC) (Research Diets, diet # D12108) and LFNC diet groups with and without ezetimibe (30 mg/kg/day; Schering-Plough, New Brunswick, NJ, added to powdered food) and the mice continued on these diets for 2 weeks before tumor implantation. Xenografts were initiated by injecting LNCaP (2 x 10^6 per site) with 1:1 volume of Matrigel (BD BioSciences, San Jose, CA) into the four dorsal quadrants of each animal. To eliminate any injection bias, the mice were randomized before implantation and the implanter was blinded to which group each mouse was assigned. All animal procedures were done in compliance with Children's Hospital Boston's animal care and use policies. Tumors were measured daily from the initiation of the first palpable tumors and the mice were sacrificed before reaching the maximum tumor burden (~13 days post implantation). Terminal bleeds were taken (cardiac puncture) for serology (triglyceride, bilirubin and other liver function tests) were performed in the Dept. of Laboratory Medicine, Children's Hospital Boston; androgen levels were determined by a testosterone EIA, Diagnostic Systems Laboratories, Webster, TX). Tumors were removed, measured, weighed, and either

Figure 1. Diet/ezetimibe effects on serum cholesterol levels and the growth of implanted prostate tumors in SCID mice. A: Serum cholesterol levels in diet/ezetimibe mouse cohorts. Animals were given various ezetimibe (Z)-diet combinations (see Figure) for 2 weeks after which the mice were bled by small tail vein incision, and cholesterol measured in the collected serum via Infinity colorimetric assay. Data are plotted as cholesterol level (mg/dL) vs. group ± SE. n = 13 to 15/group. Two-way analysis of variance indicated significant effects of diet (F = 77.57, P < 0.001) and drug (F = 23.48, P < 0.001) on cholesterol levels, but no significant diet-by-drug interaction (F = 0.86, P = 0.36) suggesting that the effects are independent. B: Longitudinal volume measurements. SCID mice were fed various diet/ezetimibe (Z) combinations for 2 weeks before tumor implantation (see Materials and Methods). Tumors were measured daily by calipers starting at first appearance (day 1) and continued for 13 days. Data are plotted as tumor volume (mm^3) per site versus time (days) ± SE. A mixed model analysis was used to calculate the significance of the both diet (P = 0.048) and ezetimibe (Z) (P = 0.035) on tumor growth. n = 52 to 60/group. C: Tumor wet weight. At sacrifice all tumors were removed and weighed. Data are plotted as average tumor mass (g) per site versus group ± SE. These data were statistically significant between LFNC + Z (0.03 ± 0.05 average grams/tumor site) vs. HFHC (0.88 ± 0.71 average grams/tumor site) groups (P = 0.021) and between the LFNC (0.67 ± 0.56 average grams/tumor site) vs. HFHC groups (P = 0.057). n = 52 to 60/group. In all cases data are considered significant at P < 0.05.
Figure 2. Biochemical and cell biological tumor characteristics. A: Tumor cholesterol levels. Membranes were prepared from tumors and subjected to cholesterol extraction and analysis (see Materials and Methods). Data are plotted as cholesterol (mg/g) tumor tissue versus diet/ezetimibe (Z) group ± SE. Data were analyzed by analysis of variance, which indicated no significant interaction between diet and ezetimibe (P = 0.40) but highly significant main effects of both diet (P = 0.039) and ezetimibe (P < 0.0001) (n = 9/group).

B: Tumor cell apoptosis (TUNEL staining). Upper panel: representative TUNEL stained images. Left column shows TUNEL staining (fluorescein; green) of selected tumor sections; right column is the merged image of TUNEL and DAPI counterstaining, (n = 40).

Lower panel: quantitative evaluation of tumor cell apoptosis levels. Data are plotted as relative level of TUNEL staining versus diet/ezetimibe (Z) group ± SE. Data were analyzed by analysis of variance, which indicated no significant interaction between diet and ezetimibe (P = 0.85) but highly significant main effects of both diet (P < 0.0001) and ezetimibe (P < 0.0001).

C: Tumor cell proliferation (Ki-67 staining). Upper panel: representative Ki-67 stained images. Left column, Ki-67 staining (red); Right column, merged image of Ki-67 (Cy3; red) and DAPI (blue; nuclei) counterstaining, (n = 20).

Lower panel: quantitative evaluation of tumor cell proliferation levels. Data are plotted as relative level of Ki-67 staining versus diet/ezetimibe (Z) group ± SE. The data were analyzed by two-way analysis of variance, which demonstrated that there is a significant ezetimibe by diet interaction (P = 0.027), implying that ezetimibe has a significant effect on lowering proliferation although the magnitude of this effect depends on the diet. LFNC: average 28.78 (95% CI; 25.42 to 32.14) w/ezetimibe: average 25.57 (95% CI; 22.21 to 28.93); HFHC: average 41.16 (CI; 37.80 to 44.52) w/ezetimibe: average 30.32 (95% CI, 26.96 to 33.68). Images were acquired and analyzed by AxioVision 4.0 software for quantification. In all cases data are considered significant at P < 0.05.
placed in optimal cutting temperature (OCT) solution (Tissue-Tek, Torrance, CA) or snap frozen.

Cell Culture
LNCaP human prostate tumor cells (American Type Culture Collection, Manassas, VA), which do not express either caveolin or phosphatase and tensin homolog were cultured in RPMI (Invitrogen, Carlsbad, CA) media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 5% CO2 at 37°C.

Tumor Cholesterol Analysis
Tumors were finely minced in PBS on ice and the level of cholesterol was determined as described previously.26

Apoptosis
Percentage of apoptotic cells in tumor sections was determined by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using the In Situ Cell Death Detection Kit (Roche Diagnostics Corp, Indianapolis, IN). Briefly, frozen tumor sections were fixed in 4% paraformaldehyde, permeabilized and the DNA stained with fluorescein following the manufacturer’s instructions. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI, Vector Labs, Burlingame, CA). Images were captured using a Zeiss microscope and the positive cells and nuclei were counted using Axiovision 4.0 software.

Immunofluorescence
Tumor samples frozen in OCT were sectioned (at 3 to 20 μm), mounted on Superfrost slides (ThermoFisher Scientific, Waltham, MA), and air-dried for 30 minutes. Sections were then fixed using cold acetone (5 minutes), followed by 1:1 acetone:chloroform (5 minutes), and then acetone centrifugation (to remove debris) and the clarified supernatants were analyzed by optical density (absorbance at 530Å —absorbance at 650Å). Data are plotted as average caveolin-1 signal (arbitrary units) vs. diet/ezetimibe (Z) group

Figure 3. Angiogenesis in xenograft tumors. A: Tumor hemoglobin quantification. Tumors were subjected to mechanical disruption in PBS, followed by centrifugation (to remove debris) and the clarified supernatants were analyzed by optical density (absorbance at 530Å —absorbance at 650Å). Data are plotted as average hemoglobin/mg tumor tissue versus group (mean value is indicated by line). All groups demonstrated statistical significance versus all other groups except for LFNC versus HFHC + Z (ezetimibe), and LFNC versus LFNC + Z, which were not statistically different. n = 20. B: MVD-CD31 analysis. Upper panel: quantitative evaluation of tumor section CD31 levels. Data are plotted as relative level of CD31 staining versus diet/ezetimibe (Z) group ± SE. Data were analyzed by mixed model analysis, which indicated no significant interaction between diet and ezetimibe (P = 0.199) but highly significant main effect of ezetimibe (P = 0.015) with larger effects when the HFHC was used (P = 0.01). Lower panel: representative anti-CD31 mAb stained images. Left column, CD31 staining (Alexa Fluor 488, Green); Right column, merged image of CD31 (Alexa Fluor 488; Green) and DAPI (blue; nuclei) counterstaining. Percentage of apoptotic cells in tumor sections was determined by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using the In Situ Cell Death Detection Kit (Roche Diagnostics Corp, Indianapolis, IN). Briefly, frozen tumor sections were fixed in 4% paraformaldehyde, permeabilized and the DNA stained with fluorescein following the manufacturer’s instructions. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI, Vector Labs, Burlingame, CA). Images were captured using a Zeiss microscope and the positive cells and nuclei were counted using Axiovision 4.0 software.

Statistics
To assess the effects of drug and diet on growth as well as microvessel density, pericyte coverage, and TSP-1

Lysates and Immunoblotting
Tumors were finely minced in 1 ml of fresh PBS on ice. The minced tissue suspensions were centrifuged at 10,000 × g at 4°C (2 minutes) and the supernatant removed. The optical density of the clarified supernatants was read at 650 nm (background) and 530 nm (hemoglobin) using a spectrophotometer.49,50

Hemoglobin Assay
Tumors were finely minced in 1 ml of fresh PBS on ice. The minced tissue suspensions were centrifuged at 10,000 × g at 4°C (2 minutes) and the supernatant removed. The optical density of the clarified supernatants was read at 650 nm (background) and 530 nm (hemoglobin) using a spectrophotometer.
levels in xenograft tumors in SCID mice, a mixed-model analysis of variance was used to account for the repeated measurements within the same tumor or animal and multiple time points.\textsuperscript{51} Compound symmetry covariance structure was incorporated to model the within-animal correlation and provided the best fit to the data as judged by Akaike's information criterion.\textsuperscript{52} Data for tumor cholesterol, apoptosis, and proliferation were analyzed using
two-way analysis of variance with diet and drug as factors in the 2 × 2 factorial experiment and diet-by-drug interaction term in the models to ascertain whether the diet and drug effects are independent main effects or conditional. Simple comparisons were performed using the standard unpaired Student’s t-test. Statistical analysis was performed with SPSS software (version 15.0, SPSS Inc., Chicago, IL). Two-tailed values of P < 0.05 were considered statistically significant.

**Results**

The atherogenic Paigen diet is the standard method for raising levels of circulating cholesterol in mice. The Paigen diet causes severe liver toxicity and contains sodium cholate, a bile acid, and liver toxin. To isolate the effect of cholesterol from other factors under conditions more relevant to human diets, we attempted to raise cholesterol using a HFHC diet without sodium cholate. Application of this diet resulted in significantly elevated serum cholesterol levels (Figure 1A), thus allowing the comparison of mice made hypercholesterolemic by this diet to animals fed a normocholesterolemic LFNC diet. These diets are isocaroric, excluding any possibility of an energy effect. A subset of mice on both diets was treated with ezetimibe (30 mg/kg/d) to lower cholesterol.

Initially, cholesterol levels were normalized in all animals using the LFNC diet for 2 weeks. Average cholesterol level was 147.47 ± 17.25 mg/dL (range 112.07 to 214.66 mg/dL). Note that standard mouse chow contains only 0.002% (w/w) cholesterol and this level of cholesterol in the diet does not alter murine serum cholesterol levels versus a diet containing no cholesterol (data not shown). Two mice with the lowest and highest cholesterol levels were eliminated from the study because cholesterol varied by more than 2 SD from the average. Fifty-eight mice were then randomly assigned to 1 of 4 diet/drug groups: (1) LFNC, (2) LFNC+ezetimibe (Z), (3) HFHC, and (4) HFHC+Z. Calorie intake was set at 21.18 Kcal/d in all groups. Observation indicated that ezetimibe did not alter feeding behavior. Animals were kept on the regimens for 2 weeks, and cholesterol levels determined, at which point serum cholesterol levels were significantly different between the four cohorts (Figure 1A). Ezetimibe caused significant reductions in serum cholesterol in both the LFNC and HFHC diet groups.

Following alteration of cholesterol levels, the animals were injected subcutaneously with 2 × 10^6 LNCAp cells/site in their flanks (four tumors/mouse). Regimens were continued following implantation, and the experiment continued for 13 days following the initial appearance of tumors. Tumor volume was measured daily (Figure 1B). Significantly reduced tumor growth rates were observed with the LFNC diet (P = 0.048) and by added ezetimibe (P = 0.035). The overall effect of diet and ezetimibe was independent and additive, not synergistic. HFHC tumor wet weights at sacrifice were significantly larger than tumors in the other groups (Figure 1C; LFNC drug (0.63 ± 0.55 g) vs. HFHC (0.88 ± 0.71 g), P = 0.021; LFNC (0.67 ± 0.56 g) vs. HFHC, P = 0.037). Tumor take was >95% in all groups and no significant differences in tumor take between groups were observed. We expected that long-term maintenance on the HFHC diet might raise serum triglycerides; conversely, ezetimibe has been reported to exert a modest reduction of triglyceride levels in humans. However, in the present study, the HFHC diet did not result in statistically significant increases in serum triglycerides, nor were triglyceride levels significantly reduced in the ezetimibe cohorts (data not shown). Serological testing (AST, ALP, bilirubin, etc) indicated no liver dysfunction in any mouse (data not shown).

To investigate the mechanisms behind the apparent tumor-promoting effect of elevated cholesterol, we examined the tumors using a variety of approaches. The level of membrane cholesterol in the tumors reflected the serum cholesterol levels in vivo (Figure 2A). Tumor cholesterol levels were independently affected by both ezetimibe and by diet. Apoptosis and cell proliferation were evaluated quantitatively in the tumors. Apoptosis was significantly increased by the LFNC diet (P < 0.0001) and independently by ezetimibe (P < 0.0001), however, no synergy was observed (P = 0.85) (Figure 2B). Cell proliferation, as measured by Ki-67 staining, was greater in the HFHC tumors and, independently, when ezetimibe was omitted (Figure 2C). A significant diet/ezetimibe interaction (P = 0.027) was observed using cell proliferation as an endpoint.

In processing the xenografts, we noted that tumors from the HFHC mice were bloodier than tumors from...
other cohorts. Relative hemoglobin levels correlated positively with circulating cholesterol level (Figure 3A), suggesting a potential effect of cholesterol on vascular penetration into the tumors. Microvessel density (MVD) was quantified using an antibody for CD31 (PECAM), an endothelial cell marker. MVD was significantly suppressed by both ezetimibe and by the LFNC diet when compared with the HFHC diet (Figure 3B). A similar result was observed when caveolin-1, which is expressed at high levels by murine endothelial cells but not by LNCaP cells, was used as an independent assessment of MVD. MVD was not simply a reflection of tumor size because no correlation was observed between tumor size and MVD when similar-sized tumors from each cohort were compared ($r = 0.05; P = 0.39$).

The increase in endothelial cells in tumors grown under hypercholesterolemic conditions suggested the possibility that other stromal cell components may also be affected by the increase in cholesterol level. To assess what contribution fibroblasts made to the tumor we stained tumor sections using a fibroblast specific monoclonal antibody (Figure 4A). This analysis revealed a statistically significant increase in the number of fibroblasts in tumors grown under hypercholesterolemic conditions. Ezetimibe treatment significantly reduced the number of fibroblasts found in the tumors, but only when the HFHC diet was used. Blood vessels undergoing rapid angiogenesis in tumors tend to exhibit poor vascular morphology, characterized by low pericyte recruitment. Pericyte coverage of vessels was dramatically increased in the ezetimibe groups (Figure 4B), suggesting a stabilizing effect of lower levels of circulating cholesterol on blood vessel structure. These results strongly suggest that one or more angiogenic factor(s) might be responsible for the observed effects, but after extensive testing we could not find any differences in the cohorts in the pro-angiogenic factors VEGF or bFGF expression (data not shown). Because in our prior studies we had shown that hypercholesterolemia leads to increased activation of the serine-threonine kinase Akt, and Akt is known to reduce expression of TSP-1, a potent angiogenic suppressor, we examined TSP-1 levels in the tumors. Here we found highly significant differences in TSP-1 levels, which were enhanced by both the LFNC diet and ezetimibe (Figure 4C). Collectively, these results indicate a pronounced effect of circulating cholesterol on mechanisms of angiogenesis.

**Discussion**

We have presented evidence that circulating cholesterol, in isolation from other factors, stimulates the growth of human prostate tumors *in vivo* and, conversely, that cholesterol lowering slows tumor growth. Our conclusion that the effects we describe can be attributed to cholesterol is supported by the following evidence: 1) tumor growth closely corresponded to serum cholesterol level; 2) we used isocaloric diets, eliminating any potential effect of energy imbalance on tumor growth; 3) cholesterol lowering was accomplished with the drug ezetimibe (Zetia), which blocks both dietary and biliary cholesterol uptake by targeting NPC1L1, a gut transporter responsible for essentially all uptake of dietary cholesterol; ezetimibe is believed at this time to be specific for NPC1L1; 4) the diet interventions did not affect testosterone levels (data not shown), consequently these results cannot be attributed to availability of androgen; 5) triglyceride levels were not altered by diet or decreased by ezetimibe treatment, and all liver function tests were normal; and 6) serum cholesterol levels correlated significantly with tumor cholesterol levels, apoptotic tumor cell number, tumor cell proliferation, and MVD.

The most dramatic effect elicited by the manipulation of circulating cholesterol levels was its impact on tumor angiogenesis. Our studies revealed that reducing cholesterol levels reduces the amount of tumor-associated blood and blood vessels, and increases vessel pericyte coverage (suggesting more stable vascular structure), while raising the tumor-associated levels of TSP-1, a potent inhibitor of angiogenesis. These results strongly suggest that a major biological effect of hypercholesterolemia on prostate tumors is increased angiogenesis. An important implication of these findings is the possibility that cholesterol reduction, which is routinely accomplished pharmacologically in humans, may reduce angiogenesis, ultimately leading to less aggressive tumors. These data are consistent with published data showing that long-term (>5 yrs) cholesterol lowering therapy, principally through the use of statin drugs, reduces the risk of advanced PCa.

The increase in endothelial cell numbers as a consequence of hypercholesterolemia suggested that tumors might also exhibit an increase in other stromal cell components. We analyzed the tumors using a fibroblast-specific marker and determined that the hypercholesterolemic cohort (ie, fed the HFHC diet without ezetimibe) had a statistically significant greater number of fibroblasts than the other cohorts, although as a proportion of the total number of cells in the tumors, the fibroblasts were in general a very small cellular component (see Figure 4A). A role for stromal fibroblasts in promoting tumor progression has been described, including the ability of stromal fibroblasts to stimulate angiogenesis through increased levels of stromal cell-derived factor-1. Cholesterol has been shown to promote proliferation and to regulate nitric oxide signaling in fibroblasts, but a specific role for cholesterol in activities that may mediate tumor fibroblast stimulation of tumor growth has not, to our knowledge, been described. Our current efforts suggest that hypercholesterolemia either increases the recruitment or *in situ* proliferation of stromal fibroblasts, where they perhaps contribute to the promotion of tumor growth.

In these experiments we demonstrate that ezetimibe blocks the accelerated tumor growth stimulated by the HFHC diet, and even reduces the more modest tumor growth in mice fed a LFNC diet. Ezetimibe works by
blocking intestinal uptake of dietary cholesterol and bile-derived cholesterol; thus, the drug is expected to reduce circulating cholesterol levels even when there is no cholesterol in the diet.\textsuperscript{41–44} Consistent with this expectation, we found that ezetimibe reduced serum cholesterol levels in mice with no cholesterol in their diet. Unlike statins, which block cholesterol synthesis at an early step in the mevalonate pathway, and thus suppress production of upstream intermediates (including isoprenoids), ezetimibe only blocks cholesterol-uptake and likely has no direct effect on other components of the pathway. Ezetimibe has been shown to have a modest effect on reducing triglyceride levels in humans,\textsuperscript{41,42} but in our studies in mice we found no reduction of serum triglyceride levels, suggesting that altered triglycerides did not contribute to ezetimibe’s effects. Our studies also demonstrate that a combination of a LFNC diet and ezetimibe reduces tumor growth additively.

Although we do not know the precise mechanism by which lower serum cholesterol results in reduced tumor growth, our investigations demonstrate that TSP-1 levels are inversely correlated to the level of serum cholesterol. TSP-1 is a multifunctional 450-kDa extracellular matrix glycoprotein and the first endogenous inhibitor of angiogenesis to be discovered. It is critical to the formation and progression of solid tumors including regulating proliferation, adhesion, migration, and angiogenesis. Our observation that hypercholesterolemia decreases expression of the angiogenesis inhibitor TSP-1 is consistent with prior reports that TSP-1 overexpression inhibits the growth of prostate tumor xenografts in mice.\textsuperscript{64} LNCAp cells express both TSP-1 as well as its major receptor CD36.\textsuperscript{65} TSP-1 has been shown to directly inhibit cell proliferation and stimulate apoptosis.\textsuperscript{65} Thus, it is possible that under hypercholesterolemic conditions the reduction in TSP-1 levels is a direct contributor to the increased angiogenesis, increased tumor cell proliferation, and the decreased apoptosis that we observed. The potential for cholesterol to regulate TSP-1, and, potentially, other angiogenesis inhibitors, is not known, although one study reported increased TSP-1 expression in the rabbit aorta under hypercholesterolemic conditions.\textsuperscript{66} Regulation of vascular mediators by circulating cholesterol appears to be a productive area for investigation. Interestingly, CD36 localizes to cholesterol-enriched lipid raft membranes,\textsuperscript{67} a subcellular compartment that, in tumors, sequesters higher levels of cholesterol under conditions of hypercholesterolemia.\textsuperscript{12} Whether increased cholesterol in the serum and/or in tumor cell membranes alters TSP-1 signals mediated by CD36 is not known.

The results of these experiments cannot easily be extrapolated to anticipate the effects of cholesterol lowering/raising in the context of human prostate cancer, due to limitations of the model we used. First, the xenograft site (subcutaneous flank) has a very different vascular bed than that which is present in the prostate. Because angiogenesis appears to be a major mediator of ezetimibe’s effect on tumor growth, the physiological actions of the drug may differ in situations where the degree of vascularity and proximity to the circulatory system are different. Second, because the experiments described here involve xenografts generated from tumorigenic cells, our studies only address a role for cholesterol in tumor progression, not tumor initiation. However, our studies do suggest the possibility that chemopreventive intervention to inhibit PCA progression by lowering cholesterol pharmacologically, possibly in combination with diet, may be effective in humans.

Acknowledgments
We thank Diane Bielenberg, Jack Lawler, and the late Judah Folkman, for their advice and critical comments.

References


